Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

Share Price is delayed by 15 minutes
Get Live Data
7.75    0.03 (0.39%)
Bid:
7.50
Ask:
8.00
Spread: 0.50 (6.667%)
Market Cap: £50.79m
KMK Live PriceLast checked at - London Stock Exchange

Intraday Kromek Share Chart

New Nuclear Security order from US federal entity

25 May 2022 07:00

RNS Number : 6866M
Kromek Group PLC
25 May 2022
 

25 May 2022

 

Kromek Group plc

("Kromek" or the "Group")

 

Kromek receives new Nuclear Security order from US federal entity

Repeat order received for D3S-ID 'dirty bomb' detector

 

Kromek (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces that it has received an order from a US federal entity for the Group's D3S-ID wearable nuclear radiation detector. The order is worth $695,000 and is to be delivered in the coming months. This is a repeat order for the D3S-ID from this customer, following the award of a $1.6m two-year contract in September 2021.

 

The D3S-ID is designed to enable first responders, armed forces, border security and other CBRN experts to detect radiological threats such as dirty bombs, radioactive contamination and smuggling of radioactive substances. It is a wearable gamma neutron RIID (radioisotope identification device) that the Group believes is one of the fastest and most accurate isotope identification devices in its class on the market. Kromek's D3S platform - comprising the Group's range of D3S products - is widely deployed as a networked solution to protect cities, buildings, or critical infrastructure.

 

Dr Arnab Basu, CEO of Kromek, said: "We're pleased to have received this latest order for our D3S-ID nuclear radiation detector that provides security authorities with an early warning system for potential threats. Being awarded a repeat order for this product from this important customer is a great endorsement. With the volatility of the current geopolitical environment, we are receiving heightened demand for our CBRN solutions, from new and existing customers, as governments become increasingly aware of the need to enhance their real-time threat monitoring. We believe that our solutions are best placed to provide them with this capability and, accordingly, we expect to receive further orders for our nuclear security products in the near term."

 

 

For further information, please contact:

 

Kromek Group plc 

Arnab Basu, CEO 

Paul Farquhar, CFO 

+44 (0)1740 626 060 

 

 

finnCap Ltd (Nominated Adviser and Broker) 

 

Geoff Nash/Kate Bannatyne/George Dollemore - Corporate Finance

+44 (0)20 7220 0500

Tim Redfern/Charlotte Sutcliffe - ECM

 

Luther Pendragon (Financial PR) 

Harry Chathli/Claire Norbury 

+44 (0)20 7618 9100 

 

 

About Kromek Group plc

 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions. 

 

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

 

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation technology, are primarily used to protect critical infrastructure and urban environments from the threat of 'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens. 

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

 

Further information is available at www.kromek.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFZLLLLELZBBE
Date   Source Headline
4th Jun 20267:00 amRNSGrant of Long-Term Incentives
2nd Jun 20267:00 amRNS-RLaunch of new interactive investor hub
1st Jun 20267:00 amRNSPDMR/Director Shareholding, Issue of Equity & TVR
12th May 20267:00 amRNSFull Year 2026 Trading Update
30th Apr 20262:30 pmRNSIssue of Equity, TVR & Extension of Options
9th Mar 20261:36 pmRNSDirector Share Purchase
9th Mar 20261:36 pmRNSDirector Share Purchase
20th Jan 20267:00 amRNSInterim Results
16th Dec 20257:00 amRNSNotice of Results
15th Dec 202512:27 pmRNSHolding(s) in Company
3rd Nov 202511:32 amRNSDirector Share Purchase
28th Oct 20257:00 amRNSGrant of Options, PDMR Dealings and TVR
27th Oct 20252:16 pmRNSResult of AGM
27th Oct 20257:00 amRNSPre-close Trading Statement
3rd Oct 202510:06 amRNSNotice of AGM and Publication of Annual Report
16th Sep 20257:00 amRNSFinal Results
11th Aug 20257:00 amRNSNew Biosecurity Award from UK MoD
28th Jul 20257:00 amRNS$5m received under Siemens Healthineers agreement
21st Jul 20257:00 amRNS£1.7m contract win under UK Government Framework
23rd Jun 202511:40 amRNS-RCapital Markets Day Presentation
18th Jun 20257:00 amRNSCapital Markets Day
16th Jun 20254:02 pmRNSHolding(s) in Company
9th Jun 20257:00 amRNSIssue of Equity and Total Voting Rights
3rd Jun 20251:53 pmRNSHolding(s) in Company
3rd Jun 20257:00 amRNSCapital Markets Day
28th May 20257:00 amRNSNew Nuclear Security Orders
8th May 20257:05 amRNSDirectorate Change
8th May 20257:00 amRNSFull Year 2025 Trading Update
17th Feb 20257:00 amRNS$25m received under Siemens Healthineers agreement
7th Feb 20251:49 pmRNSHolding(s) in Company
6th Feb 202512:35 pmRNSHolding(s) in Company
30th Jan 20257:01 amRNSInterim Results
30th Jan 20257:00 amRNSKromek Signs Agreements with Siemens Healthineers
13th Dec 202412:20 pmRNSResult of AGM
18th Nov 20247:00 amRNSNotice of AGM and Publication of Annual Report
28th Oct 20247:01 amRNSFinal Results and Publication of Annual Report
28th Oct 20247:00 amRNSFinancing Update
30th Sep 20247:00 amRNSUpdate on Full Year Results
23rd Sep 20247:00 amRNSKromek selected for UK Government Framework
16th Sep 20247:00 amRNSKromek awarded £2.0m contract from UK MOD
21st Aug 202410:14 amRNSHolding(s) in Company
7th Jun 20249:20 amRNSCancellation of outstanding Convertible Loan Notes
29th May 20247:00 amRNSFY 2024 Trading Update
25th Apr 20247:00 amRNSKromek receives new Nuclear Security contract
3rd Apr 20243:13 pmRNSDirector/PDMR Shareholding
26th Mar 20247:00 amRNSKromek receives $2.1m security screening order
6th Mar 20243:21 pmRNSHolding(s) in Company
4th Mar 202412:16 pmRNSHolding(s) in Company
4th Mar 202411:51 amRNSResult of General Meeting
5th Feb 202410:17 amRNSConversion of £1.5m of Convertible Loan Notes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.